| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We tried to evaluate the expression of long non-coding RNAs (lncRNAs) in scleroderma patients and determined whether lncRNAs controls collagen expression in dermal fibroblasts. lncRNA expression was examined by real-time PCR and in situ hybridization. We found one of the lncRNAs, TSIX, was overexpressed in scleroderma dermal fibroblasts both in vivo and in vitro. TSIX siRNA decreased the mRNA expression of type I collagen in normal and sclerderma dermal fibroblasts. Furthermore, TSIX siRNA significantly reduced type I collagen mRNA stability, but not protein half-lives. We first showed that serum TSIX levels were significantly increased in scleroderma patients. TSIX siRNA also attenuated the dermal thickening induced by bleomycin injection.
Our study demonstrated that TSIX plays a role in the pathogenesis of scleroderma, and may become a key molecule to develop novel diagnostic tool or therapeutic approach.
|
